Shots:

• Tessa to conduct a P-Ib/II trial assessing Tessa’s human papillomavirus-specific T cell (HPVST) therapy or TT12 with Merck’s Keytruda (pembrolizumab) for patients with recurrent or metastatic HPV 16 and 18-positive cervical cancer
• The P-Ib/II trial will be initiated in the US- Singapore- South Korea. Additionally- Tessa’s TT12 and an anti PD-1 therapy is being evaluated in P-I for patients with relapsed HPV-associated cancers- resulted in well-tolerated and minimal toxicity results in the US
• Tessa’s TT12 is an autologous cell therapy based on HPVSTs targeting HPV 16/18 antigens and genetically modified with a decoy TGF-β receptor. Keytruda (pembrolizumab) is an anti-PD-1 therapy involves blocking of the interaction between PD-1 and its ligands i.e PD-L1 & PD- L2

Ref: Tessa Therapeutics | Image: Merck